Unknown PHASE3 INTERVENTIONAL 2-arm NCT04303598

Phase III Clinical Study of Azvudine in Hiv-infected Treatment Naive Patients

A Randomized, Double-blind, Double-simulated, Active-controlled，Phase III Clinical Study Evaluating the Efficacy and Safety of Azvudine Combined With Tenofovir Fumarate and Efavirenz in Hiv-infected Treatment Naive Patients

Sponsor: Henan Genuine Biotech Co., Ltd.

Conditions HIV-infection/Aids

Interventions 3TC 3TC placebo EFV FNC FNC placebo TDF

Updated 6 times since 2020 Last updated: Mar 6, 2020 Started: Apr 1, 2020 Primary completion: May 1, 2022 Completion: Aug 1, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04303598, this PHASE3 trial focuses on HIV-infection/Aids and remains ongoing. Sponsored by Henan Genuine Biotech Co., Ltd., it has been updated 6 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Jun 2025 — Present [monthly]

Unknown PHASE3
Sep 2024 — Jun 2025 [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Nov 2022 — Jul 2024 [monthly]

Unknown Status PHASE3

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Nov 2022 [monthly]

Not Yet Recruiting PHASE3

▶ Show 1 earlier version

Apr 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Henan Genuine Biotech Co., Ltd.

Data source: Henan Genuine Biotech Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Changsha, China , Chengdu, China , Chongqing, China , Guangzhou, China , Hangzhou, China , Harbin, China , Nanjing, China , Tianjin, China , Wuhan, China and 1 more location